Overview

  • Product name

  • Description

    Rabbit polyclonal to MEK1 + MEK2
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WB, IHC-P, ICC/IFmore details
  • Species reactivity

    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide conjugated to KLH, surrounding amino acids 216-220 and 220-224 (

    IDSMA

    ) of Human MEK1 + MEK2 (NP_002746.1, NP_109587.1).

  • Positive control

    • HeLa cells; 293 cell extract; Human lung carcinoma tissue.

Properties

  • Form

    Liquid
  • Storage instructions

    Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
  • Storage buffer

    pH: 7.40
    Preservative: 0.02% Sodium azide
    Constituents: 48% PBS, 50% Glycerol, 0.88% Sodium chloride
    Note: PBS without Mg2+ and Ca2+
  • Concentration information loading...
  • Purity

    Immunogen affinity purified
  • Purification notes

    ab131517 was purified by affinity chromatography using epitope specific peptide.
  • Clonality

    Polyclonal
  • Isotype

    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab131517 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/1000. Predicted molecular weight: 44 kDa.
IHC-P 1/50 - 1/100.
ICC/IF 1/100 - 1/200.

Target

  • Function

    Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leading to their activation and further transduction of the signal within the MAPK/ERK cascade. Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis.
  • Tissue specificity

    Widely expressed, with extremely low levels in brain.
  • Involvement in disease

    Cardiofaciocutaneous syndrome 3
  • Sequence similarities

    Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
    Contains 1 protein kinase domain.
  • Domain

    The proline-rich region localized between residues 270 and 307 is important for binding to RAF1 and activation of MAP2K1/MEK1.
  • Post-translational
    modifications

    Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinase kinases (RAF or MEKK1) positively regulates kinase activity. Also phosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK. MAPK1/ERK2 phosphorylation of Thr-292 occurs in response to cellular adhesion and leads to inhibition of Ser-298 phosphorylation by PAK.
    Acetylation by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.
  • Cellular localization

    Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Cytoplasm, cytoskeleton, microtubule organizing center, spindle pole body. Cytoplasm. Nucleus. Localizes at centrosomes during prometaphase, midzone during anaphase and midbody during telophase/cytokinesis.
  • Information by UniProt
  • Database links

  • Alternative names

    • AA589381 antibody
    • CFC3 antibody
    • Dual specificity mitogen-activated protein kinase kinase 1 antibody
    • Dual specificity mitogen-activated protein kinase kinase 2 antibody
    • EC 2.7.12.2 antibody
    • ERK activator kinase 1 antibody
    • ERK activator kinase 2 antibody
    • FLJ26075 antibody
    • MAP kinase kinase 1 antibody
    • MAP kinase kinase 2 antibody
    • MAP2K1 antibody
    • MAP2K2 antibody
    • MAPK/ERK kinase 1 antibody
    • MAPK/ERK kinase 2 antibody
    • MAPKK 1 antibody
    • MAPKK1 antibody
    • MAPKK2 antibody
    • MEK 1 antibody
    • MEK1 antibody
    • MEKK1 antibody
    • Mitogen activated protein kinase kinase 1 antibody
    • Mitogen activated protein kinase kinase 2 antibody
    • Mitogen-activated protein kinase kinase 2, p45 antibody
    • MK2 antibody
    • MKK 1 antibody
    • MKK 2 antibody
    • MKK1 antibody
    • MKK2 antibody
    • MP2K1_HUMAN antibody
    • PRKMK 1 antibody
    • PRKMK 2 antibody
    • Prkmk1 antibody
    • Prkmk2 antibody
    • protein kinase, mitogen-activated, kinase 1 (MAP kinase kinase 1) antibody
    • Protein kinase, mitogen-activated, kinase 1 antibody
    • Protein kinase, mitogen-activated, kinase 2 antibody
    see all

Images

  • All lanes : Anti-MEK1 + MEK2 antibody (ab131517) at 1/500 dilution

    Lane 1 : 293 cell extract with blocking peptide
    Lane 2 : 293 cell extract

    Predicted band size: 44 kDa

  • Immunofluorescent analysis of methanol-fixed HeLa cells labelling MEK1 + MEK2 with ab131517 at 1/100 dilution.
  • Immunohistochemical analysis of paraffin-embedded Human lung carcinoma tissue labelling MEK1 + MEK2 with ab131517 at 1/50 dilution. The image on the right is treated with the synthesized peptide.

References

This product has been referenced in:

  • Fang L  et al. Icariin inhibits cell proliferation, migration and invasion by down-regulation of microRNA-625-3p in thyroid cancer cells. Biomed Pharmacother 109:2456-2463 (2019). Read more (PubMed: 30551506) »
See 1 Publication for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab131517.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up